Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015;6(2):127-31.
doi: 10.1080/21505594.2015.1011532.

Impact of daptomycin resistance on Staphylococcus aureus virulence

Affiliations

Impact of daptomycin resistance on Staphylococcus aureus virulence

David R Cameron et al. Virulence. 2015.

Abstract

Daptomycin resistance (DAP(R)) in Staphylococcus aureus is associated with mutations in genes that are also implicated in staphylococcal pathogenesis. Using a laboratory-derived series of DAP exposed strains, we showed a relationship between increasing DAP MIC and reduced virulence in a Galleria mellonella infection model. Point mutations in walK and rpoC led to cumulative reductions in virulence and simultaneous increases in DAP MIC. A point mutation to mprF did not impact on S.aureus virulence; however deletion of mprF led to virulence attenuation and hyper-susceptibility to DAP. To validate our findings in G. mellonella, we confirmed the attenuated virulence of select isolates from the laboratory-derived series using a murine septicaemia model. As a corollary, we showed significant virulence reductions for clinically-derived DAP(R) isolates compared to their isogenic, DAP-susceptible progenitors (DAP(S)). Intriguingly, each clinical DAP(R) isolate was persistent in vivo. Taken together, it appears the genetic correlates underlying daptomycin resistance in S. aureus also alter pathogenicity.

Keywords: Galleria mellonella; S. aureus; bacterial persistence; mprF; walK.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Daptomycin resistance in S. aureus correlates with altered virulence and in vivo persistence. (A) G. mellonella infection of a laboratory-derived series of isolates with incremental increases in daptomycin MIC was performed (n = 16 for each strain). For clarity, CB1618-d6, CB1618-d9, CB1618-d13, CB1618-d20 are represented by d6, d9, d13 and d20 respectively. Virulence attenuation was observed for CB1618-d9 when compared to CB1618-d6 (P < 0.01) and CB1618-d20 when compared with CB1618-d13 (P < 0.01). No significant virulence attenuation was observed for CB1618-d6 (P = 0.44) and CB1618-d13 (P = 0.70) when compared to their respective progenitor strains. (B) An mprF deletion strain (CB1118ΔmprF) produced significantly less killing of G. mellonella when compared to its progenitor (P < 0.001, n = 16 for each strain). (C) CB1618-d9 and CB1618-d20 were attenuated for virulence in a murine septicaemia model (P < 0.001, n = 10 for each strain). (D) CB1618-d9 was capable of in vivo persistence as determined by bacterial densities in the kidneys of mice 7-days post infection. In contrast, bacterial burden was not observed in the kidneys of mice infected with CB1618-d20. (E) Virulence of 3 DAP-exposed clinical pairs was assessed using a murine septicaemia model. The daptomycin-resistant (R) isolates were significantly attenuated for virulence compared to their susceptible progenitors (S) (P < 0.001, n = 15 for each strain) and (F) were persistent in the kidneys of infected mice out to 7-days post-infection.

Similar articles

Cited by

References

    1. Fowler VG, Jr., Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, Levine DP, Chambers HF, Tally FP, Vigliani GA, et al. . Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006; 355:653-65; PMID:16914701; http://dx.doi.org/10.1056/NEJMoa053783 - DOI - PubMed
    1. Hayden MK, Rezai K, Hayes RA, Lolans K, Quinn JP, Weinstein RA. Development of Daptomycin resistance in vivo in methicillin-resistant Staphylococcus aureus. J Clin Microbiol 2005; 43:5285-7; PMID:16207998; http://dx.doi.org/10.1128/JCM.43.10.5285-5287.2005 - DOI - PMC - PubMed
    1. Marty FM, Yeh WW, Wennersten CB, Venkataraman L, Albano E, Alyea EP, Gold HS, Baden LR, Pillai SK. Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis. J Clin Microbiol 2006; 44:595-7; PMID:16455920; http://dx.doi.org/10.1128/JCM.44.2.595-597.2006 - DOI - PMC - PubMed
    1. Ernst CM, Staubitz P, Mishra NN, Yang SJ, Hornig G, Kalbacher H, Bayer AS, Kraus D, Peschel A. The bacterial defensin resistance protein MprF consists of separable domains for lipid lysinylation and antimicrobial peptide repulsion. PLoS Pathog 2009; 5:e1000660; PMID:19915718; http://dx.doi.org/10.1371/journal.ppat.1000660 - DOI - PMC - PubMed
    1. Peleg AY, Miyakis S, Ward DV, Earl AM, Rubio A, Cameron DR, Pillai S, Moellering RC, Jr., Eliopoulos GM. Whole genome characterization of the mechanisms of daptomycin resistance in clinical and laboratory derived isolates of Staphylococcus aureus. PLoS One 2012; 7:e28316; PMID:22238576; http://dx.doi.org/10.1371/journal.pone.0028316 - DOI - PMC - PubMed

Publication types